ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT06425991

Public ClinicalTrials.gov record NCT06425991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma

Study identification

NCT ID
NCT06425991
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
108 participants

Conditions and interventions

Interventions

  • Teclistamab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 6, 2024
Primary completion
Feb 27, 2027
Completion
Mar 2, 2027
Last update posted
Apr 12, 2026

2024 – 2027

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234
Colorado Blood Cancer Institute Denver Colorado 80218
Cleveland Clinic Florida Weston Florida 33331
Augusta University- Georgia Cancer Center Augusta Georgia 30912
St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health Indianapolis Indiana 46237
Cleveland Clinic Cleveland Ohio 44195
Baylor University Medical Center Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06425991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06425991 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →